Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15421246 | 1.00 | CHRM2 (0.49) | CHRM2CHRM4CHRM5L3MBTL1KMT2A | |
| SCHEMBL10106310 | 1.00 | CHRM2 (0.49) | CHRM2CHRM4CHRM5L3MBTL1KMT2A | |
| SCHEMBL21548123 | 0.90 | CHRM2 (0.43) | CHRM2CHRM4CHRM5L3MBTL1KMT2A | |
| SCHEMBL6153627 | 0.88 | CHRM2 (0.56) | CHRM2CHRM4CHRM5L3MBTL1KMT2A | |
| SCHEMBL636999 | 0.86 | CHRM2 (0.58) | CHRM2CHRM4CHRM5L3MBTL1KMT2A | |
| SCHEMBL29691892 | 0.84 | CHRM2 (0.53) | CHRM2CHRM4CHRM5L3MBTL1ALDH1A1 | |
| SCHEMBL707808 | 0.84 | CHRM2 (0.53) | CHRM2CHRM4CHRM5L3MBTL1ALDH1A1 | |
| SCHEMBL719296 | 0.84 | CHRM2 (0.53) | CHRM2CHRM4CHRM5L3MBTL1ALDH1A1 | |
| SCHEMBL19364501 | 0.84 | CHRM2 (0.53) | CHRM2CHRM4CHRM5L3MBTL1ALDH1A1 | |
| SCHEMBL16766368 | 0.84 | CHRM2 (0.53) | CHRM2CHRM4CHRM5L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| CN-113382767-B | Urea compounds having substituents | 第一三共株式会社 | 2024-12-24 | — | — | CN | disclosed |
| US-11981686-B2 | Urea compound having substituent | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-14 | — | — | US | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-5641786-A | Quinuclidine derivatives | LOWE III JOHN ADAMS (US) | 1997-06-24 | — | — | US | disclosed |
| US-5422354-A | Quinuclidine derivatives | PFIZER INC (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0540526-B1 | QUINUCLIDINE DERIVATIVES | PFIZER (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0623621-A1 | Oxazabicyclo derivatives and their use as 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0540526-A1 | QUINUCLIDINE DERIVATIVES. | PFIZER (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001688-A1 | QUINUCLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-02-06 | — | — | WO | disclosed |
| US-4352802-A | DESALINATION OF SEA WATER | BEECHAM GROUP LIMITED (GB) | 1982-10-05 | — | — | US | disclosed |
| EP-0041817-A1 | Benzamide derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981686-B2 | Urea compound having substituent | SIRT6, SIRT1, SIRT2 | CHRM2 2071/4885CHRM4 3251/4885CHRM5 2947/4885 |
| US-20230287003-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | CHRM2 4751/4885CHRM4 4697/4885CHRM5 4734/4885 |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | SIRT6, SIRT1, SIRT2 | CHRM2 2071/4885CHRM4 3251/4885CHRM5 2947/4885 |
| US-12486285-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | CHRM2 4751/4885CHRM4 4697/4885CHRM5 4734/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | CHRM2 4733/4885CHRM4 4720/4885CHRM5 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.